The shares of this main pharmaceutical firm are in focus after the corporate secured the USFDA’s approval for its key drug used to deal with ovarian most cancers. On this article, we’ll dive deep into its particulars.
With a market capitalisation of Rs 20,494 crores, the shares of Alembic Prescribed drugs Ltd are presently buying and selling at Rs 1,043 per share, down by 19.53 % from its 52-week excessive of Rs 1,296.15 per share. Over the previous 5 years, the inventory has delivered a poor return of 13.58 %.
The agency disclosed in a inventory change doc that it has been granted closing clearance from the US FDA for its generic model of Doxorubicin Hydrochloride Liposome Injection.
The drug might be provided in 20 mg/10 mL and 50 mg/25 mL single-dose vials. The permitted drug is claimed to be equal to the branded title, Doxil, produced by Baxter Healthcare, as it may be used in its place for a similar remedy.
Doxorubicin Hydrochloride Liposome Injection is a remedy possibility for Ovarian Most cancers, AIDS-related Kaposi’s Sarcoma, and A number of Myeloma. This drug works by slowing down or halting the expansion of most cancers cells. The liposomal formulation is designed to attenuate uncomfortable side effects by delivering the medicine extra on to the most cancers cells.
Monetary Highlights
The corporate reported a income of Rs 6,672 crores in FY25, up by 7.11 % from its FY24 income of Rs 6,229 crores. Nonetheless, the corporate reported a web revenue decline of 5.51 % to Rs 582 crore in FY25 from Rs 616 crores in FY24.
The inventory delivered an ROE and ROCE of 11.35 % and 13.05 %, respectively, and is presently buying and selling at a P/E of 36.08x as in comparison with its trade common of 32.71x.
Alembic Prescribed drugs Restricted manufactures and markets generic pharmaceutical merchandise all around the world. Alembic’s state-of-the-art analysis and manufacturing services are permitted by regulatory authorities of many developed international locations, together with the USFDA. Alembic is likely one of the leaders in branded generics in India. Alembic’s manufacturers, marketed by way of a subject power of over 5500, are nicely acknowledged by medical doctors and sufferers.
Written by Satyajeet Mukherjee
Disclaimer
The views and funding suggestions expressed by funding specialists/broking homes/score companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Buyers should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the creator should not accountable for any losses brought on because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
